Kringle Pharma, Inc. (TYO:4884)

Market Cap	3.42B
Revenue (ttm)	72.00M
Net Income (ttm)	-902.00M
Shares Out	6.84M
EPS (ttm)	-133.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,400
Average Volume	214,220
Open	500.00
Previous Close	505.00
Day's Range	494.00 - 508.00
52-Week Range	494.00 - 1,322.00
Beta	0.33
RSI	18.81
Earnings Date	Aug 8, 2025

About Intra-Cellular Therapies

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 15
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4884

Financial Performance

In 2024, Kringle Pharma's revenue was 80.00 million, an increase of 15.94% compared to the previous year's 69.00 million. Losses were -756.00 million, -11.48% less than in 2023.